Business Description
Simulations Plus Inc
NAICS : 513210
SIC : 7372
ISIN : US8292141053
Total Employee Number:
213Description
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 102.65 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-EBITDA | 0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 17.07 | |||||
Beneish M-Score | -3.02 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.9 | |||||
3-Year EBITDA Growth Rate | -6.4 | |||||
3-Year EPS without NRI Growth Rate | -18.6 | |||||
3-Year FCF Growth Rate | 2.2 | |||||
3-Year Book Growth Rate | -11 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.32 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.45 | |||||
9-Day RSI | 63.71 | |||||
14-Day RSI | 63.41 | |||||
3-1 Month Momentum % | 9.69 | |||||
6-1 Month Momentum % | 49.88 | |||||
12-1 Month Momentum % | 28.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.54 | |||||
Quick Ratio | 5.54 | |||||
Cash Ratio | 3.68 | |||||
Days Sales Outstanding | 64.07 | |||||
Days Payable | 14.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 0.11 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.38 | |||||
Operating Margin % | 14.02 | |||||
Net Margin % | 9.88 | |||||
EBITDA Margin % | 20.86 | |||||
FCF Margin % | 26.39 | |||||
OCF Margin % | 30.4 | |||||
ROE % | 6.25 | |||||
ROA % | 5.76 | |||||
ROIC % | 7.39 | |||||
3-Year ROIIC % | -16.14 | |||||
ROC (Joel Greenblatt) % | 83.05 | |||||
ROCE % | 8.84 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 46 | |||||
Forward PE Ratio | 38.72 | |||||
PE Ratio without NRI | 29.16 | |||||
Shiller PE Ratio | 96.81 | |||||
Price-to-Owner-Earnings | 25.56 | |||||
PS Ratio | 4.53 | |||||
PB Ratio | 2.68 | |||||
Price-to-Tangible-Book | 5.49 | |||||
Price-to-Free-Cash-Flow | 17.16 | |||||
Price-to-Operating-Cash-Flow | 14.91 | |||||
EV-to-EBIT | 28.05 | |||||
EV-to-EBITDA | 18.85 | |||||
EV-to-Revenue | 3.93 | |||||
EV-to-Forward-Revenue | 4.7 | |||||
EV-to-FCF | 14.9 | |||||
Price-to-GF-Value | 0.52 | |||||
Price-to-Projected-FCF | 1.26 | |||||
Price-to-Median-PS-Value | 0.33 | |||||
Price-to-Graham-Number | 2.67 | |||||
| Price-to-Net-Current-Asset-Value | 6.07 | |||||
| Price-to-Net-Cash | 10.34 | |||||
Earnings Yield (Greenblatt) % | 3.57 | |||||
FCF Yield % | 5.82 | |||||
Forward Rate of Return (Yacktman) % | 1.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SLP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Simulations Plus Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 82.058 | ||
| EPS (TTM) ($) | 0.4 | ||
| Beta | 1.378 | ||
| 3-Year Sharpe Ratio | -0.35 | ||
| 3-Year Sortino Ratio | -0.46 | ||
| Volatility % | 45.54 | ||
| 14-Day RSI | 63.41 | ||
| 14-Day ATR ($) | 0.068988 | ||
| 20-Day SMA ($) | 18.3585 | ||
| 12-1 Month Momentum % | 28.9 | ||
| 52-Week Range ($) | 11.09 - 21.01 | ||
| Shares Outstanding (Mil) | 20.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Simulations Plus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Simulations Plus Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2027-02-12 14:00 | In 168 days | ||
| First quarter earnings conference call for 2027 | 2027-01-08 17:00 | In 133 days | ||
| First quarter earnings results for 2027 | 2027-01-08 | In 132 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-12-01 17:00 | In 95 days | ||
| Annual report for 2026 | 2026-12-01 | In 94 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-01 | In 94 days | ||
| Third quarter earnings conference call for 2026 | 2026-07-09 | 18.27 (-0.16%) | ||
| Third quarter earnings results for 2026 | 2026-07-09 | 18.27 (-0.16%) | ||
| Project Optimus: Oncology Dose Optimization Based on Clinical Pharmacology Strategy and MIDD Approach | 2026-05-26 11:00 | 15.37 (+0.39%) | ||
| Second quarter earnings conference call for 2026 | 2026-04-09 17:00 | 13.00 (-1.52%) |
Show
Entries
Simulations Plus Inc Frequently Asked Questions
What is Simulations Plus Inc(SLP)'s stock price today?
The current price of SLP is $18.40. The 52 week high of SLP is $21.01 and 52 week low is $11.09.
When is next earnings date of Simulations Plus Inc(SLP)?
The next earnings date of Simulations Plus Inc(SLP) is 2026-12-01 Est..
Does Simulations Plus Inc(SLP) pay dividends? If so, how much?
Simulations Plus Inc(SLP) does not pay dividend.
Guru Commentaries on NAS:SLP
Conestoga SMid Cap Composite
Bearish
2025 Q2
What the manager wrote
Simulations Plus, Inc. (SLP) faced challenges this quarter due to lowered guidance stemming from drug research funding and tariff uncertainty. This resulted in a drop in its stock price. The manager noted that SLP was one of the largest detractors from relative return within the Technology sector, indicating concerns about its performance amidst broader market conditions.
Conestoga Small Cap Composite
Bearish
2025 Q2
What the manager wrote
Simulations Plus, Inc. (SLP) faced challenges this quarter due to lowered guidance stemming from drug research funding and tariff uncertainty. This resulted in a drop in its stock price. The manager noted that SLP was one of the largest detractors from relative return within the Technology sector, indicating concerns about its performance amidst broader market conditions.
Conestoga Micro Cap Composite
Bearish
2025 Q2
What the manager wrote
Simulations Plus, Inc. (SLP) faced challenges this quarter due to lowered guidance stemming from drug research funding and tariff uncertainty. This resulted in a drop in its stock price. The company was one of the largest detractors from relative return within the Technology sector, indicating significant headwinds that may impact its performance going forward.
Press Release
Articles on Simulations Plus Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers